AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8001357 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior probability distribution of vaccine efficacy
Number of subjects: 0
Study 8001357 — intervention group
Group type: EXPERIMENTAL
Intervention: Probability of regulatory approval for widespread use of the vaccine
Number of subjects: 0
Study 8001357 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal stopping policy
Number of subjects: 0
Study 3390997 — intervention group
Group type: EXPERIMENTAL
Intervention: gallopamil 37.5 mg t.i.d.
Number of subjects: 32
Study 3390997 — intervention group
Group type: EXPERIMENTAL
Intervention: gallopamil 50 mg t.i.d.
Number of subjects: 32
Study 3390997 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study 8256213 — intervention group
Group type: COMPARATOR
Intervention: Levothyroxine at substitutive dosage (100 micrograms)
Number of subjects: 60
Study 8256213 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine at suppressive dosage (2.2 to 3 micrograms/kg/day)
Number of subjects: 60
Study 356724 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (1 g every 6 h)
Number of subjects: 100
Study 356724 — intervention group
Group type: COMPARATOR
Intervention: Penicillin (600,000 U every 6 h)
Number of subjects: 100
Study 356724 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 100
Study 356724 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 100
Study 31339594 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarpogrelate with high-dose statin (Group A, n = 25)
Number of subjects: 100
Study 31339594 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarpogrelate with low-dose or no statin (Group B, n = 25)
Number of subjects: 100
Study 31339594 — intervention group
Group type: COMPARATOR
Intervention: Placebo with high-dose statin (Group C, n = 25)
Number of subjects: 100
Study 31339594 — intervention group
Group type: COMPARATOR
Intervention: Placebo with low-dose or no statin (Group D, n = 25)
Number of subjects: 100
Study 31339594 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 100
Study 31339594 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose statin (compared to low-dose or no statin)
Number of subjects: 100
Study 31339594 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal TIMI flow on initial provocation test
Number of subjects: 100
Study 28024770 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect bonding group
Number of subjects: 64
Study 28024770 — intervention group
Group type: COMPARATOR
Intervention: Direct bonding group
Number of subjects: 64
Study 25651203 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with partial tenonectomy (group A)
Number of subjects: 46
Study 25651203 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy alone (group B)
Number of subjects: 46
Study 24773263 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 42
Study 24773263 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 42
Study 21946012 — intervention group
Group type: EXPERIMENTAL
Intervention: General mental imagery
Number of subjects: 0
Study 21946012 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referential mental imagery
Number of subjects: 0
Study 21946012 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic visual imagery
Number of subjects: 0
Study 21946012 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex types of imagery
Number of subjects: 0
Study 21946012 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic memory deficits
Number of subjects: 0
Study 21946012 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact basic mental imagery and rehearsal
Number of subjects: 0
Study 19569965 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01B
Number of subjects: 102
Study 19569965 — intervention group
Group type: COMPARATOR
Intervention: RTS,S/AS02A
Number of subjects: 102
Study 17289576 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine, an inhibitor of prolactin secretion
Number of subjects: 0
Study 17289576 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced myocardial generation of 16 kDa prolactin
Number of subjects: 0
Study 17289576 — intervention group
Group type: COMPARATOR
Intervention: PPCM patients
Number of subjects: 0
Study 15356502 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary occlusal splints
Number of subjects: 16
Study 15356502 — intervention group
Group type: COMPARATOR
Intervention: No splints (control)
Number of subjects: 16
Study 15356502 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing‐like movement
Number of subjects: 16
Study 12195694 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamin supplements (5 mg folic acid, 0.4 mg hydroxycobalamin, and 50 mg pyridoxine) daily for 8 weeks
Number of subjects: 118
Study 12195694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 12195694 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamin supplements
Number of subjects: 118
Study 9894361 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 0
Study 8017326 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed powder (10 g/d)
Number of subjects: 18
Study 2808261 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) at a mean maximal daily oral dose of 4.6 +/- 0.2 mg/kg for 6 weeks.
Number of subjects: 58
Study 2808261 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) for 6 additional weeks in 27 placebo nonresponders.
Number of subjects: 58
Study 2808261 — intervention group
Group type: EXPERIMENTAL
Intervention: DMI treatment above 3.5 mg/kg.
Number of subjects: 58
Study 2808261 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 58
Study 1096927 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g ascorbic acid daily
Number of subjects: 8
Study 30813776 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin and serial casting
Number of subjects: 10
Study 30813776 — intervention group
Group type: EXPERIMENTAL
Intervention: Splinting and motor training following serial casting
Number of subjects: 10
Study 30813776 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait list for six weeks)
Number of subjects: 10
Study 28711114 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit ABM training protocol
Number of subjects: 45
Study 28711114 — intervention group
Group type: COMPARATOR
Intervention: Implicit ABM training protocol
Number of subjects: 45
Study 28711114 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit-Explicit ABM training protocol
Number of subjects: 45
Study 28711114 — intervention group
Group type: EXPERIMENTAL
Intervention: All training protocols
Number of subjects: 45
Study 27533964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mangafodipir (MnDPDP)
Number of subjects: 20
Study 27533964 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 20
Study 23498759 — intervention group
Group type: EXPERIMENTAL
Intervention: Infra-low-frequency transcranial magnetic stimulation (in addition to conventional comprehensive rehabilitation therapy)
Number of subjects: 75
Study 23498759 — intervention group
Group type: COMPARATOR
Intervention: Conventional comprehensive rehabilitation therapy
Number of subjects: 75
Study 21332798 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic combination plus pre-biotics
Number of subjects: 1018
Study 21332798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1018
Study 18250112 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzbromarone 200 mg/day
Number of subjects: 62
Study 18250112 — intervention group
Group type: COMPARATOR
Intervention: Probenecid 2 g/day
Number of subjects: 62
Study 16721856 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone plus Interferon
Number of subjects: 48
Study 16721856 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alone
Number of subjects: 48
Study 16721856 — intervention group
Group type: COMPARATOR
Intervention: Untreated children
Number of subjects: 48
Study 15164330 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (500 mg orally at 2 am and again at 6 am)
Number of subjects: 10
Study 15164330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10676671 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 296
Study 10676671 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 296
Study 10676671 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 296
Study 10676671 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic agents
Number of subjects: 296
Study 10676671 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated group
Number of subjects: 296
Study 10676671 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual NTG
Number of subjects: 296
Study 10676671 — intervention group
Group type: EXPERIMENTAL
Intervention: NG‐monomethyl‐L‐arginine (NO synthase inhibitor)
Number of subjects: 296
Study 10676671 — intervention group
Group type: COMPARATOR
Intervention: Normotensive subjects (Control)
Number of subjects: 296
Study 9354513 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue sprayed on the 'raw' lung surface
Number of subjects: 66
Study 9354513 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrin glue)
Number of subjects: 66
Study 1488570 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled gallopamil (10 mg)
Number of subjects: 8
Study 1488570 — intervention group
Group type: COMPARATOR
Intervention: Control (no gallopamil)
Number of subjects: 8
Study 3003883 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber diet
Number of subjects: 80
Study 3003883 — intervention group
Group type: COMPARATOR
Intervention: Low-fiber diet
Number of subjects: 80
Study 31688396 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (20 mg/d)
Number of subjects: 40
Study 31688396 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 40
Study 30338820 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF‐beta1
Number of subjects: 3
Study 30338820 — intervention group
Group type: COMPARATOR
Intervention: High glucose
Number of subjects: 3
Study 28835359 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antibodies against malaria vaccine candidate antigens
Number of subjects: 33
Study 28835359 — intervention group
Group type: COMPARATOR
Intervention: Mothers with placental malaria
Number of subjects: 33
Study 28835359 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination of mothers with malaria vaccine during pregnancy
Number of subjects: 33
Study 25642909 — intervention group
Group type: EXPERIMENTAL
Intervention: SonixGPS ultrasound needle guidance system activated
Number of subjects: 26
Study 25642909 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrasound (control group)
Number of subjects: 26
Study 23902797 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed intervention (adjunct motivational and autonomy-enhancing approach)
Number of subjects: 72
Study 23902797 — intervention group
Group type: COMPARATOR
Intervention: Prescribed intervention (standard prescription of uniform behavioral skills use and interventionist goal assignment)
Number of subjects: 72
Study 23902797 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed intervention
Number of subjects: 72
Study 23902797 — intervention group
Group type: COMPARATOR
Intervention: Prescribed intervention
Number of subjects: 72
Study 20430503 — intervention group
Group type: EXPERIMENTAL
Intervention: knowledge-contact program
Number of subjects: 89
Study 20430503 — intervention group
Group type: COMPARATOR
Intervention: knowledge program
Number of subjects: 89
Study 18253904 — intervention group
Group type: EXPERIMENTAL
Intervention: Open access colonoscopy with trainee participation
Number of subjects: 368
Study 18253904 — intervention group
Group type: COMPARATOR
Intervention: Open access colonoscopy without trainee participation
Number of subjects: 368
Study 16959744 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass surgery
Number of subjects: 281
Study 16959744 — intervention group
Group type: COMPARATOR
Intervention: On-pump coronary artery bypass surgery
Number of subjects: 281
Study 16959744 — intervention group
Group type: COMPARATOR
Intervention: Control group (112 volunteers not undergoing surgery)
Number of subjects: 281
Study 12840090 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (2 mg per kilogram per day)
Number of subjects: 155
Study 12840090 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (1.5 mg per kilogram of body weight per day)
Number of subjects: 155
Study 10373765 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamically oriented treatment, median duration of therapy approximately 11 weeks.
Number of subjects: 1171
Study 10373765 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamically oriented treatment
Number of subjects: 1171
Study 8712092 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg
Number of subjects: 124
Study 8712092 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 80 mg
Number of subjects: 124
Study 8712092 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 100 mg
Number of subjects: 124
Study 8712092 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 124
Study 1714270 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation
Number of subjects: 498
Study 1714270 — intervention group
Group type: COMPARATOR
Intervention: Untreated eyes (Control)
Number of subjects: 498
Study 7332916 — intervention group
Group type: EXPERIMENTAL
Intervention: Flubendazole, 100 mg twice a day for three days
Number of subjects: 40
Study 7332916 — intervention group
Group type: COMPARATOR
Intervention: Mebendazole, 100 mg twice a day for three days
Number of subjects: 40
Study 7332916 — intervention group
Group type: EXPERIMENTAL
Intervention: Flubendazole and Mebendazole
Number of subjects: 40
Study 31037733 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye movement desensitization and reprocessing intervention (6 sessions)
Number of subjects: 90
Study 31037733 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye movement desensitization and reprocessing intervention
Number of subjects: 90
Study 28867499 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir 50 mg, Emtricitabine 200 mg, Tenofovir Alafenamide 25 mg
Number of subjects: 657
Study 28867499 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir 50 mg, Emtricitabine 200 mg, Tenofovir Alafenamide 25 mg
Number of subjects: 657
Study 27004302 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-Discharge Formula (PDF)
Number of subjects: 20
Study 27004302 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Protein, Medium-Chain Triglyceride Containing Formula (HPMCT)
Number of subjects: 20
Study 23490572 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-delivered brief alcohol intervention (BAI) plus treatment as usual (TAU)
Number of subjects: 167
Study 23490572 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 167
Study 21488763 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance for MRSA and VRE colonization and expanded use of barrier precautions in intervention ICUs.
Number of subjects: 5434
Study 21488763 — intervention group
Group type: COMPARATOR
Intervention: Existing practice in control ICUs.
Number of subjects: 5434
Study 19833610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of autologous mononuclear bone marrow cells (mBMCs), n=50
Number of subjects: 100
Study 19833610 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mBMCs), n=50
Number of subjects: 100
Study 16540613 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine and psychotherapy
Number of subjects: 116
Study 16540613 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine and clinical-management sessions
Number of subjects: 116
Study 16540613 — intervention group
Group type: COMPARATOR
Intervention: Placebo and psychotherapy
Number of subjects: 116
Study 16540613 — intervention group
Group type: COMPARATOR
Intervention: Placebo and clinical-management sessions
Number of subjects: 116
Study 12620292 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha‐2c (3.5 MU/d) plus araC (10 mg/m(2) d1‐10)
Number of subjects: 114
Study 12620292 — intervention group
Group type: COMPARATOR
Intervention: IFN alpha‐2c (3.5 MU/d) plus hydroxyurea (HU: 25 mg/kg per day)
Number of subjects: 114
Study 11095473 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous GH infusion (2 IU/m2-24 h)
Number of subjects: 5
Study 11095473 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile GH administration (eight bolus injections)
Number of subjects: 5
Study 11095473 — intervention group
Group type: EXPERIMENTAL
Intervention: Both continuous and pulsatile GH administration
Number of subjects: 5
Study 8143950 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 70
Study 8143950 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 70
Study 3510458 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.3 mg and 0.6 mg
Number of subjects: 100
Study 3510458 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine 30 mg and 60 mg
Number of subjects: 100
Study 30572423 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen use (ever use)
Number of subjects: 281
Study 30572423 — intervention group
Group type: COMPARATOR
Intervention: Never use of tamoxifen
Number of subjects: 281
Study 30572423 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 281
Study 30572423 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease
Number of subjects: 281
Study 25753488 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg daily
Number of subjects: 306
Study 25753488 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 306
Study 25035172 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line response by receiving agencies classified into 3 categories: plan for action only, some action taken, and no plan and no action taken.
Number of subjects: 3706
Study 25035172 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral of children based on predefined criteria for violence disclosure.
Number of subjects: 3706
Study 25035172 — intervention group
Group type: EXPERIMENTAL
Intervention: Help seeking behavior of children prior to the baseline survey.
Number of subjects: 3706
Study 22882761 — intervention group
Group type: EXPERIMENTAL
Intervention: de‐Leval's method
Number of subjects: 161
Study 22882761 — intervention group
Group type: EXPERIMENTAL
Intervention: Flam's modification
Number of subjects: 161
Study 20516676 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil 75 mg once daily (OD) in the evening (group O; n = 41)
Number of subjects: 80
Study 20516676 — intervention group
Group type: COMPARATOR
Intervention: Naftopidil 25 mg thrice daily (TID) in the morning, afternoon, and evening (group T; n = 39)
Number of subjects: 80
Study 18230388 — intervention group
Group type: EXPERIMENTAL
Intervention: He-Ne laser (lambda = 632.8nm, output = 10 mW, energy density = 1.8 J/cm(2)) for 8 days, followed by laser probe treatment at 6 anatomic sites for 5 minutes each.
Number of subjects: 24
Study 18230388 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 24
Study 15866959 — intervention group
Group type: EXPERIMENTAL
Intervention: Techni-Care (3.0% chloroxylenol)
Number of subjects: 125
Study 15866959 — intervention group
Group type: EXPERIMENTAL
Intervention: DuraPrep (0.7% iodine and 74% isopropyl alcohol)
Number of subjects: 125
Study 15866959 — intervention group
Group type: EXPERIMENTAL
Intervention: ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol)
Number of subjects: 125
Study 12030875 — intervention group
Group type: EXPERIMENTAL
Intervention: Avène spring water spray in conjunction with petrolatum ointment
Number of subjects: 74
Study 12030875 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum ointment alone
Number of subjects: 74
Study 10334658 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.83 g plant sterols
Number of subjects: 100
Study 10334658 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.61 g plant sterols
Number of subjects: 100
Study 10334658 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.24 g plant sterols
Number of subjects: 100
Study 8772751 — intervention group
Group type: EXPERIMENTAL
Intervention: Subintimal resection
Number of subjects: 525
Study 8772751 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimal resection
Number of subjects: 525
Study 1349666 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy plus axillary dissection
Number of subjects: 658
Study 1349666 — intervention group
Group type: COMPARATOR
Intervention: Lumpectomy alone
Number of subjects: 658
Study 3971682 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled intravenous (i.v.) morphine sulfate for 24 hours
Number of subjects: 20
Study 3971682 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (i.m.) morphine sulfate for 24 hours
Number of subjects: 20
Study 3971682 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled intravenous (i.v.) morphine sulfate
Number of subjects: 20
Study 3971682 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (i.m.) morphine sulfate
Number of subjects: 20
Study 30875381 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS)
Number of subjects: 3511
Study 30875381 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CDS)
Number of subjects: 3511
Study 29175749 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby-CIMT
Number of subjects: 37
Study 29175749 — intervention group
Group type: COMPARATOR
Intervention: Baby-massage
Number of subjects: 37
Study 27406165 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 86
Study 24769640 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Number of subjects: 0
Study 24769640 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (DTIC)
Number of subjects: 0
Study 24769640 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib after crossover from DTIC
Number of subjects: 0